AD/PD 2026 Conference Alzheimer's Preclinical and Clinical Data Extraction
This report covers 41 clinical abstracts from AD/PD 2026, spanning Phase 1–3 trial updates, real-world evidence, and biomarker readouts across 30 named interventions. Anti-amyloid immunotherapy — led by lecanemab and donanemab — dominates the landscape, while valiltramiprosate (ALZ-801) emerges as the most active late-stage challenger with Phase 3 data showing cognitive benefits and hippocampal atrophy reversal in APOE4/4 homozygotes. Biomarker innovation, neuroinflammation, and non-amyloid pathways signal a field actively broadening beyond antibody-mediated amyloid clearance.
Read the full report
Enter your details below to access the complete analysis — clinical timelines, competitive landscape, and analyst commentary.
Want a report like this for your target?
We build custom intelligence reports scoped to your therapeutic area, asset, or investment thesis.
Book a Call